News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) To Report A Whopping $400 Million 4th Quarter In High-Profile EyeDrug Sales



1/15/2014 6:16:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - Regeneron Pharmaceuticals Inc will report about $400 million in U.S. sales of its high-profile eye drug Eylea for the fourth quarter of 2013, bringing the total for the year to about $1.4 billion with lots of room for future sales growth, the U.S. biotech company's chief executive said on Tuesday.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES